✦ LIBER ✦

Correction: Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial

✍ Scribed by Manal F. Abdelmalek; Schuyler O. Sanderson; Paul Angulo; Consuelo Soldevila-Pico; Chen Liu; Joy Peter; Jill Keach; Matt Cave; Theresa Chen; Craig J. McClain; Keith D. Lindor

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 46 KB
Volume: 51
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.23642

No coin nor oath required. For personal study only.

✦ Synopsis

Data describing cirrhosis prevalence in the simple steatosis group reported in the study by Rafiq et al. should read NR (not reported) instead of 42 (56.8%). All cirrhosis prevalence proportions were calculated based upon these correct (NR) data.

📜 SIMILAR VOLUMES

Betaine for nonalcoholic fatty liver dis

Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial

✍ Manal F. Abdelmalek; Schuyler O. Sanderson; Paul Angulo; Consuelo Soldevila-Pico 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 227 KB 👁 1 views

Based on animal studies and pilot studies in humans, betaine, a methyl donor for the remethylation of homocysteine, may be a therapeutic agent for nonalcoholic steatohepatitis (NASH). We evaluated the safety and efficacy of betaine for patients with NASH and whether betaine positively modified facto

Lifestyle intervention and antioxidant t

Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial

✍ Valerio Nobili; Melania Manco; Rita Devito; Vincenzo Di Ciommo; Donatella Compar 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB 👁 1 views

No proven treatment exists for nonalcoholic fatty liver disease (NAFLD) in children and adolescents. We sought to determine the efficacy of lifestyle intervention with or without antioxidant therapy in pediatric NAFLD. A total of 53 patients (age 5.7-18.8 years, 37 boys) were included. Lifestyle int

Suggestion of a dual-functional agent fo

Suggestion of a dual-functional agent for future trials in nonalcoholic fatty liver disease

✍ Liang Shen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 411 KB 👁 1 views

We read with great interest the practice guidelines for the diagnosis and management of autoimmune hepatitis recently issued by the American Association for the Study of Liver Diseases (AASLD). 1 In particular, we appreciate the new definition of biochemical remission, which now requires not only no

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease

✍ J. P. Wright; Dr. D. P. Jewell; R. Modigliani; H. Malchow 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB 👁 1 views

Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des

Pregabalin for the treatment of fibromya

Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial

✍ Leslie J. Crofford; Michael C. Rowbotham; Philip J. Mease; I. Jon Russell; Rober 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

Risperidone for psychosis of Alzheimer's

Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial

✍ Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Cl 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Objective: To evaluate the efficacy and safety of low-dose risperidone in treating psychosis of alzheimer's disease (ad) and mixed dementia (md) in a subset of nursing-home residents who had dementia and aggression and who were participating in a randomized placebo-controlled trial of risperidon